Why NICE was right to say no—for now—to new Alzheimer's drugs by Paul Atkinson, Sally Sheard, The Conversation edited by Lisa Lock, reviewed by Andrew Zinin Editors' notes ... Credit: CC0 ...

In the US, the drugs are priced at up to £25,000 per patient per year. While companies can offer discounts to the NHS, Nice must still consider whether the same money might do more good elsewhere ...